First human trial launches for Hemay5259: a new Extended-Release drug candidate

NCT ID NCT07703904

Not yet recruiting Knowledge-focused Sponsor: Hemay Pharmaceutical PTY. LTD. Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This early-stage trial evaluates the safety, tolerability, and pharmacokinetics (how the body absorbs and processes the drug) of Hemay5259 extended-release tablets in healthy adults aged 18 to 55. Participants receive either the drug or a placebo, and the study also examines how food affects the drug's absorption. The goal is to gather essential data before moving to larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called Hemay5259 in an extended-release tablet
What this could lead to: If successful, this study could provide the safety and dosing data needed to move Hemay5259 into later trials for a potential new treatment.
What could go wrong: This is a very early Phase 1 study with only 32 healthy people, so it cannot prove the drug works for any disease. Side effects are possible and will be closely monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PHARMACOKINETICS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Scientia Clinical Research Ltd

Randwick, New South Wales, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.